Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
心脏病患者焦虑的运动和药物治疗
基本信息
- 批准号:9113594
- 负责人:
- 金额:$ 78.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcute Coronary EventAdultAdverse effectsAdverse eventAffectAmericanAmerican Heart AssociationAnti-Anxiety AgentsAnxietyAnxiety DisordersAutonomic nervous systemBiological MarkersBloodBlood VesselsCardiacCardiac rehabilitationCardiovascular systemCause of DeathCharacteristicsCholesterolChronicClinicClinicalClinical ResearchClinical Trials DesignClinical assessmentsCoronary heart diseaseDataDiagnosisEffectivenessEscitalopramEventExerciseHealthHealth Care CostsHeartHospitalizationHypertensionInflammationInterventionLexaproLiteratureMaintenanceMajor Depressive DisorderMeasuresMediatingMedicalMental DepressionMonitorMorbidity - disease rateMyocardialOdds RatioOutcomeOutpatientsParticipantPatientsPharmaceutical PreparationsPharmacotherapyPhysiologicalPlacebosPopulationPrevalencePrognostic FactorPsychosocial FactorQuality of lifeRandomizedRandomized Clinical TrialsRecommendationRegulationReportingResearchRiskRisk FactorsSelective Serotonin Reuptake InhibitorSeverity of illnessSmokingTherapeuticTimeTrainingUnited StatesWomanWorkanxiety symptomsanxiety treatmentanxiousbasecardiovascular risk factorclinically significantcostdepressive symptomsdesignexercise trainingfollow-upheart disease riskimprovedimproved outcomemenmortalityoutcome forecastprognostic significancepsychologicreduce symptomsvascular endothelial dysfunction
项目摘要
DESCRIPTION (provided by applicant): Coronary heart disease (CHD) is the leading cause of death in the United States, affecting 600,000 Americans each year. The term "cardiovascular vulnerable patient" has been used to describe patients susceptible to acute coronary events based upon plaque, blood, or myocardial characteristics. Recent evidence has suggested that anxiety, which is common in CHD patients, may be a significant and independent prognostic factor that also increases cardiovascular vulnerability. This evidence has provided a rationale for
reducing anxiety in cardiac patients. Anxiolytic medications, especially selective serotonin reuptake inhibitors (SSRIs), may be effective in this regard, although the value of these medications in reducing anxiety has not been widely studied in cardiac patients and their value in improving clinical outcomes is not known. Exercise also may be effective in reducing anxiety, although the therapeutic potential of exercise has remained unfulfilled due to a paucity of data from well-designed clinical studies. The study proposed in this application will (a) evaluate the effectiveness of exercise training and anxiolytic medication in reducing anxiety in vulnerable cardiac patients; (b) examine changes in intermediate endpoints, including measures of autonomic nervous system dysregulation, vascular endothelial dysfunction, and chronic inflammation, which also serve as physiologic markers of vulnerability to adverse cardiac events; (c) follow participants for up to 4 years to assess clinical events including fatal and non
fatal cardiac events, hospitalizations, and medical costs; and (d) explore possible mechanisms by which the interventions improve outcomes. One hundred fifty men and women with CHD and an anxiety disorder or elevated symptoms of anxiety will be randomly assigned to Exercise, Medication (escitalopram), or Placebo. Before and after 3 months of treatment, patients will undergo clinical assessments of anxiety and measures of autonomic nervous system regulation, vascular endothelial function, and inflammation. A six month follow-up will assess maintenance of psychological benefit and clinical outcomes will be monitored for up to 4 years. The data generated from this study will have important clinical significance by determining the extent to which exercise and medication may reduce anxiety, improve intermediate markers of CHD risk, and improve medical outcomes including clinical events and CHD-related hospitalizations.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James A Blumenthal其他文献
James A Blumenthal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James A Blumenthal', 18)}}的其他基金
Improving Lung Transplant Outcomes with Coping Skills and Physical Activity
通过应对技巧和体力活动改善肺移植结果
- 批准号:
10355486 - 财政年份:2019
- 资助金额:
$ 78.02万 - 项目类别:
Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
心脏病患者焦虑的运动和药物治疗
- 批准号:
9751937 - 财政年份:2015
- 资助金额:
$ 78.02万 - 项目类别:
Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
心脏病患者焦虑的运动和药物治疗
- 批准号:
8961874 - 财政年份:2015
- 资助金额:
$ 78.02万 - 项目类别:
Facility and Web-based Approaches to Lifestyle Change in Resistant Hypertension
改变顽固性高血压生活方式的设施和基于网络的方法
- 批准号:
9068412 - 财政年份:2014
- 资助金额:
$ 78.02万 - 项目类别:
Facility and Web-based Approaches to Lifestyle Change in Resistant Hypertension
改变顽固性高血压生活方式的设施和基于网络的方法
- 批准号:
9189649 - 财政年份:2014
- 资助金额:
$ 78.02万 - 项目类别:
Facility and Web-based Approaches to Lifestyle Change in Resistant Hypertension
改变顽固性高血压生活方式的设施和基于网络的方法
- 批准号:
8818651 - 财政年份:2014
- 资助金额:
$ 78.02万 - 项目类别:
Lifestyle, CVD Risk and Cognitive Impairment
生活方式、CVD 风险和认知障碍
- 批准号:
8461635 - 财政年份:2011
- 资助金额:
$ 78.02万 - 项目类别:
Lifestyle, CVD Risk and Cognitive Impairment
生活方式、CVD 风险和认知障碍
- 批准号:
8326610 - 财政年份:2011
- 资助金额:
$ 78.02万 - 项目类别:
Lifestyle, CVD Risk and Cognitive Impairment
生活方式、CVD 风险和认知障碍
- 批准号:
8840440 - 财政年份:2011
- 资助金额:
$ 78.02万 - 项目类别:
Lifestyle, CVD Risk and Cognitive Impairment
生活方式、CVD 风险和认知障碍
- 批准号:
8160913 - 财政年份:2011
- 资助金额:
$ 78.02万 - 项目类别:














{{item.name}}会员




